Bristol Myers Squibbvs.Zoetis
BMY vs ZTS · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Bristol Myers Squibb is about 3.6× larger than Zoetis by market cap; Zoetis trades at the lower P/E (12.4 vs 19.6); year to date, Bristol Myers Squibb leads (+6.7% vs −39.9%).
Side by side
| BMY | ZTS | |
|---|---|---|
| Market cap | $117B | $32.9B |
| Price | $57.58 | $75.56 |
| Today | −0.6% | +0.6% |
| Return YTD | +6.7% | −39.9% |
| Return 1Y | +18.7% | −52.4% |
| P/E | 19.6 | 12.4 |
| P/S | 2.4 | 3.5 |
| P/B | 5.8 | 10.2 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Bristol Myers SquibbBMY
American pharmaceutical group with strengths in oncology (Opdivo) and immunology, plus a neuroscience pipeline.
Full BMY profile →ZoetisZTS
The world’s largest animal health company — medicines and vaccines for pets and livestock, spun off from Pfizer in 2013.
Full ZTS profile →More comparisons in Big pharma
See where BMY and ZTS sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →